Search 

Alykomed Global Solutions LLC (AGSL), based in New York, is a respected and established provider of strategic personalized corporate solutions to the Biopharma industry. Our clients embody a wide range of companies, from innovative startups to larger established, public companies. Our projects include global business development, financial, investment, and capital support, and scientific based endeavors, among others. We are committed to our clients’ long term success, optimized growth strategies, and profitability potential.

We proudly apply our deep scientific knowledge, and combine this with our strong corporate and business development experience and an extensive scientific/business network. Our established and trusted financial investment banking service/registered broker partner, provides our clients with targeted capital and financial solutions and extensive access to institutional and retail investors. These capital services cover a wide range of investment opportunities and offerings, including, but not limited to IPOs and securities offerings, private placements, mergers and acquisition, bank and debt financing etc.

We also undertake strategic growth initiatives through global business development, researching scientific and drug development platforms, assisting with internal valuations, or assistance with other projects- we offer knowledge, experience, leadership, global awareness, and creativity. We work with a global network of professionals, having done business in North America, UK/Europe, and Asia, especially within the United States, Japan, South Korea, and China.

Contract regulatory and clinical research services, U.S. HQ with satellite offices in Taiwan and Europe.
FDA, EMA, etc. worldwide regulatory approval services for drugs, devices, and diagnostics.
Worldwide clinical testing for safety and efficacy

Aposave is the global pharmaceutical and healthcare services division of the Abacus Medicine Group.

The company mission is to assist patients with unmet medical needs get access to innovative new medicines, while assisting the manufacturers to maximise the clinical and commercial potential of their assets.

Our promise to healthcare and pharmaceutical customers is to provide a new generation of healthcare and pharmaceutical services to support their new generation of pharmaceutical products throughout the 2020’s and beyond.

To do this Aposave has developed a market leading range of services focused on providing access to medicines around the world. Working across the lifecycle in partnership with pharmaceutical and biotechnology companies Aposave creates and delivers innovative solutions that ensure patients can get timely access to the medicines they need, whilst helping pharmaceutical and biotechnology companies achieve their clinical and commercial objectives.
Aposave has a range of services to support the efficient running of clinical trials called Clinical Trial Solutions (CTS). This is an area where there are great synergies with our parent company, Abacus Medicine. The Abacus Medicine Group holds over 4500 marketing authorisations, and this provides Aposave with unrivalled access to the medicines required to support the running of clinical trials. In addition, Aposave has developed some unique approaches to minimising wastage of products that have expired or are no longer required for a trial.
Aposave has extensive knowledge and experience in managing the distribution of specialty medicines, and this service line is called Specialty Commercial Distribution (SCD). Higher value, lower volume specialty medicines often do not sit well with the traditional distribution model, and this is where our team of experts develop innovative solutions to help ensure patients have access, while maintaining the commercial requirements of our clients.
Aposave is a strategic partner to the pharmaceutical and biotech industry. Aposave Access Programs (AAP) provide a framework for a partnership where Aposave creates, implements, and manages a program on behalf of a drug manufacturer to provide access to their drug in countries where it is not commercially available. This can be either in the prelaunch, or the post launch stage of the product lifecycle. Each program is designed to meet the specific needs of the manufacturer.
The final service that Aposave provides is very much focussed on the patient, and as such is called Individual Access Requests (IAR). Patients with an unmet medical need often require access to a medicine that is not commercially available in the country where they live. When the customer service team at Aposave receive such a request from a healthcare professional, if we do not already have the product in stock, we find a source of the product and ensure we deliver it, in compliance with appropriate regulations, to the relevant medical establishment ready for the patient to receive treatment.

We are a European oncology start-up developing an entirely novel platform of small molecule drugs to cure currently untreatable cancers.We wholly own a pipeline of molecules that are active via novel mechanisms in cancer and several other therapeutic areas.
The mechanism of action of our lead drug, Ag5, targets cancer cells generating high levels of Reactive Oxygen Species (ROS). High ROS tumours are, in general, untreatable. This group of cancers includes KRAS-mutation driven cancers, which comprise around 30% of all cancer cases, and the worst prognosis group. There is currently no treatment for KRAS mutant cancers, which lead to more than 1 million deaths worldwide every year.
Glioblastoma Multiforme (GBM), the commonest primary brain cancer, is also a high-ROS cancer, despite the absence of mutated KRAS. There have been no new treatment options in GBM for 20 years, and prognosis is poor-averaging 18 months.
We have a follow-on compound and a pipeline of innovative molecules addressing both cancer and non-cancerous conditions.
We are raising a series A round which will allow us to gain clinical proof of concept.

Articulate Labs builds wearable medical devices amplify muscle growth throughout everyday activity to help others conquer functional limitations and to restore physical capability

Astrom Research International is a CRO consultancy focusing on Life Science between China and Europe.

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

DENTAL MATERIALS
STENTS
EPIDEMIC PREVENTION PRODUCTS ETC.

Bioindustry Park “Silvano Fumero” is an Italian scientific and technological park, specialized in Life Sciences, located in the Piedmont region, near Turin. Bioindustry Park promotes and develops Life Sciences research and innovation by hosting and supporting companies, start-ups and research institutions. Bioindustry Park offers a full range of services aimed at the creation and development of life sciences and health care start-up and spin-off companies not only by providing laboratories and facilities, but also through valuable scientific and business support services. Bioindustry Park “Silvano Fumero” is also the managing company of bioPmed (http://www.biopmed.eu), the Piedmont health care innovation cluster that involves private and public actors in the pharmaceutical, biotech, medtech and eHealth sectors. BioPmed gathers about 100 companies, touching the whole value chain: from research and academic institutions and foundations, to start-ups, SMEs, private and public hospitals and healthcare centers.

Canadian IVD company with core competencies in the fields of Thrombosis, Haemostasis and oncology, with innovative technologies, we collaborate internationally with technology development companies and health-care stakeholders to develop and manufacture customized reagents and diagnostic solutions.